3rd DCT, Hybrid & Centralised Clinical Trials

World Congress 2027 Europe

Where Innovation, Collaboration and Human‐Centred Design Meet

to Transform Clinical Research

 
London, United Kingdom
  • 00Days
  • 00Hours
  • 00Minutes
  • 00Seconds

Co-located with the 10th Patient Centricity & Collaboration World Congress 2027 Europe 

3rd DCT, Hybrid & Centralised Clinical Trials

Where Innovation, Collaboration and Human‐Centred Design Meet to Transform Clinical Research

Dear Colleagues,

Facilitate Live is very pleased to welcome you to our upcoming 3rd DCT, Hybrid & Centralised Clinical Trials World Congress 2027 Europe brings together a global community united by a common purpose: to shape a future where clinical research is more accessible, more connected and more responsive to the needs of people everywhere. At a time when healthcare is evolving rapidly and expectations around participation, transparency and innovation continue to rise, this Congress offers a space for reflection, collaboration and forward‐looking ambition.

Across two days, leaders from every corner of the research ecosystem will gather not simply to discuss new approaches, but to imagine what is possible when diverse perspectives come together. Whether representing pharma, biotech, CROs, academic institutions, patient organisations or government agencies, each participant contributes a vital piece of the broader vision.  The Congress celebrates this diversity of expertise, recognising that meaningful progress in clinical research can only be achieved when all voices are heard and valued.

The programme will explore how modern trial models can be shaped to better serve science and society. It will encourage attendees to look beyond individual technologies or operational processes and instead consider the bigger picture: how we design studies that are more inclusive, how we build systems that are more resilient, and how we create experiences that respect and empower the people who participate. The conversations throughout the event will highlight the importance of flexibility, empathy and shared responsibility in advancing research that truly reflects the world it aims to improve.

A central theme of the Congress is the belief that innovation is not only about new tools, but about new ways of thinking. As digital capabilities expand and remote approaches become more common, the opportunity emerges to rethink long‐standing assumptions about how trials must operate. This gathering encourages attendees to embrace curiosity, challenge convention and explore how modern methods can coexist with trusted foundations. It is an invitation to imagine trial models that are both scientifically rigorous and deeply human‐centred.

Equally important is the recognition that trust and transparency are essential to the future of research. As trials evolve, so must the ways we communicate, engage and collaborate with participants and communities. The Congress emphasises the importance of listening, truly listening, to the experiences, concerns and aspirations of patients. Their voices guide the direction of innovation and remind us that every advancement ultimately serves individuals and families seeking hope, healing and progress.

Throughout the event, attendees are encouraged to connect, share and build relationships that extend beyond the Congress itself. The challenges facing clinical research are complex, but they are also shared. By working together, across sectors, disciplines and borders, we can create trial ecosystems that are more inclusive, more efficient and more capable of meeting the needs of a changing world.

The 3rd DCT, Hybrid & Centralised Trials World Congress 2027 Europe is more than a meeting.
It is a collective commitment to shaping a future where research is accessible, equitable and grounded in collaboration. It is a celebration of what we can achieve when we unite around a shared vision: advancing clinical trials that honour both scientific excellence and the people at the heart of every study.

We look forward to welcoming you to the DCT congress!

Sincerely yours,

Jocelyn Raguindin
Conference Director
Facilitate Live

GAIN LATEST INSIGHTS ON:

WHO SHOULD ATTEND?

This Congress will provide information to pharmaceutical and biotech companies, researchers, physicians, institutional review boards (IRBs), patient organizations and advocates, and regulatory agencies about the implementation of Decentralized, Hybrid & Centralised Clinical Trials.

Network with members of the boards, VP’s, Directors, Heads/Chiefs, and Senior Managers of leading Pharmaceuticals and Biotech Companies, Government, CRO’s and Solution Providers Involved in:

Pharma & Biotech

  • Heads of Clinical Operations
  • Directors of R&D and Clinical Development
  • VPs / SVPs of Digital Health & Innovation
  • Clinical Trial Strategy Leads
  • Medical Directors & Therapeutic Area Heads
  • Heads of Patient Engagement & Diversity
  • Digital Transformation Leaders
  • Evidence Generation & Data Science Leads

Academic & Research Institutions

  • Principal Investigators
  • Clinical Research Coordinators
  • Professors of Clinical Trial Methodology
  • Digital Health Researchers
  • Biostatisticians & Methodology Experts
  • Research Ethics & Governance Leads

Patient Organisations

  • Patient Advocacy Leaders
  • Community Engagement Managers
  • Patient Advisory Board Members
  • Diversity, Equity & Inclusion Specialists

Government & Public‐Sector Agencies

  • Regulatory Affairs Leaders
  • Health Policy Advisors
  • Digital Health Programme Directors
  • Public Health Innovation Managers
  • National Research  

Technology & Digital Health Innovators

  • Technology & Digital Health Innovators
  • Founders & CEOs of Digital Health Companies
  • Product Leaders in eCOA, eConsent, Wearables & Data Platforms
  • AI & Machine Learning Leads
  • Patient Experience Designers

CROs & Service Providers

  • Clinical Operations Directors
  • Project & Programme Leaders
  • Digital Trial Delivery Specialists
  • Global Study Managers
  • Data Management & Analytics Leads
  • Patient Recruitment & Retention Strategists
  • Technology & Platform Integration Heads
speakers
0 +
days Congress
0
Presentation
0 +
Attendees
0 +

Key Industry Expert Speakers

Khadija Rantell

Senior Statistical Assessor

MHRA

Lorna Pender

Medical Director

AOP Health

Puja Myles

Director, Clinical Practice Research Datalink (CPRD)

MHRA

Alexandra Charge

Chief Executive Officer

ISPEP

Nadya Isack

Patient and Public Involvement (PPIE) Advocate, Founder,

Empower Health Initiative CIC, Person living with Obesity

Amelia Hursey

Strategic Director

parkinsonseurope.org

CAROLE SCRAFTON

CEO & Co-Founder Patient Advocacy Organisation

FibroFlutters

Dr Sondra Butterworth

CEO & Founder

RareQoL (Rare Quality of Life) and EDIRA (Equality Diversity and Inclusive Research Association)

Hannah Frost

Clinical Research Scientist

CRUK National Biomarker Centre

Dr Sachin Shah

Clinical Innovation and Digital Solutions Lead

UCB

Joanna Bell

Project Manager

Sustainable Healthcare Coalition

Elizabeth Theogaraj

Regulatory Senior Group Director

Roche

Robert Mitchell-Thain

CEO

PBC Foundation

Van Zyl Engelbrecht

Head of Country Operations / Decentralised Clinical Trials & Innovation / Rare Diseases / Regulatory Affairs

Alexion Pharmaceuticals, Inc

Rasmus Hjorth

Head of Communication

James Lind Care

Mohamed Sharaf

EMEA Regional Senior Medical Advisor (Immunology)

Johnson & Johnson

Melanie Dixon

Trustee

Cure DHDDS

Laura Risueño Ayerbe

Global Patient Affairs, Patient Engagement R&D

Servier

Cat Wilder

Chair

Von Willebrand Disease Alliance

Emma Kinloch

CEO

Salivary Gland Cancer UK

Dr Fiona Adshead

Chair

Sustainable Healthcare Coalition

Joana Claverol

Clinical Research Director

Hospital Sant Joan de Déu

Carly Santer

Strategic Advisor, Healthcare Decarbonisation

Sustainable Healthcare Coalition

Hugh Whetherly

Sr Consultant, Product Sustainability Team

ERM

Catherine Jervis

Head, DCT Market Development - EMEA

MARKEN

Emily Pickering

Specialist Commercial Services Lead, Patient Engagement in Clinical Development

NIHR Research Delivery Network

Available Shortly

Senior Representative

Coming Soon

Schedule

Content Rich Program Agenda!  Featuring Keynote Presentations, Stream Sessions, Panel, and Round Table Discussions.

Strategy, Regulation & Patient‐Centric Transformation

  • Integrating decentralised, hybrid and centralised approaches into a cohesive future‐ready ecosystem.
  • Regulatory expectations that influence digital trial design, remote data capture, and the operational frameworks required for compliance.
  • Patient‐driven priorities that shape protocol flexibility, technology usability, and the overall experience of participating in digitally‐enabled trials.
  • Collaboration models that allow pharma, CROs, tech providers and regulators to accelerate modernisation.

Moderator:


Panellists:

  • Reviewing evolving guidance on digital consent, telemedicine and remote monitoring.
  • Navigating cross‐border compliance challenges in multinational decentralised trials.
  • Assessing regulator perspectives on patient‐generated data and digital endpoints.
  • Outlining future frameworks that will shape digital trial innovation.
  • Determining when decentralisation adds value versus when centralisation is essential.
  • Evaluating digital tools across therapeutic areas for measurable operational gains.
  • Considering budgeting, ROI and resource allocation for digital transformation.
  • Building internal capabilities to support scalable hybrid trial execution.
  • Redesigning workflows to support seamless coordination between remote and on‐site activities.
  • Staff training frameworks that build confidence in digital tools and ensure consistent execution across sites.
  • Addressing multi‐vendor complexity and the operational challenges associated with fragmented technology.
  • Maintaining data quality and protocol adherence across decentralised modalities and diverse patient environments.
  • Streamlining data flows across eCOA, eConsent, wearables and telemedicine.
  • Reducing site burden through automation and integrated workflows.
  • Real‐time monitoring tools that enhance operational visibility, enabling proactive issue resolution and improved trial predictability.
  • Vendor collaboration models that support scalability, reduce fragmentation and strengthen long‐term digital infrastructure.
  • Exploring design principles that ensure digital platforms are intuitive, accessible and inclusive
  • Improving adherence through personalised digital engagement.
  • Simplifying remote procedures to reduce patient burden enabling high‐quality data capture and safety oversight.
  • How patient‐centric digital tools improve recruitment outcomes and broaden access to diverse populations?
  • Comparative outcomes from decentralised versus traditional trial designs
  • Managing methodological challenges associated with analysing patient‐generated data
  • Impact of consumer‐grade devices on data consistency and the implications for endpoint validation.
  • Future research standards that strengthen scientific rigour in decentralised methodologies.
  • National digital health frameworks that support remote trial participation and enable secure data exchange.
  • Public‐private partnerships that accelerate decentralised research and expand access to digital tools.
  • Ethical considerations related to remote data collection, privacy protection and equitable access.
  • Strategies to build public trust in digital clinical research through transparency and community engagement.
  • Identifying digital literacy gaps across patient communities and strategies to support individuals with limited technology experience.
  • Co‐designing protocols with patient groups for more practical, usable and inclusive trial experiences.
  • Exploring accessibility considerations for rare disease, mobility‐limited and geographically remote patients.
  • Approaches that strengthen trust and empower patients throughout digitally‐enabled participation.
  • Predictive analytics tools that identify emerging safety signals earlier and support proactive intervention strategies.
  • Automated remote assessment workflows to reduce manual burden and improve consistency in safety monitoring.
  • Integrating AI outputs into regulatory‐compliant processes without compromising oversight or data integrity.
  • Patient‐experience improvements enabled by timely, personalised safety interventions
  • How sites balance remote responsibilities with traditional on‐site activities while maintaining operational efficiency.
  • Addressing technology overload and presenting strategies for platform consolidation that reduce complexity.
  • Digital competency programmes that equip site staff with the skills needed to manage modern trial technologies.
  • Best practices for maintaining high‐quality data capture and patient engagement in hybrid environments.
  • Combining regulatory evolution, hybrid strategy and patient priorities into a unified direction for digital trials.
  • Integrating interoperability, technology consolidation and site readiness to strengthen operational foundations.
  • Translating academic evidence and public‐sector initiatives into practical frameworks for scalable decentralised research.
  • Building long‐term alignment across sponsors, CROs, tech providers, patients and regulators to support sustainable transformation.

Moderator:


Panellists:

Implementation, Technology & Real‐World Delivery

  • Lessons learned from real‐world decentralised and hybrid deployments across multiple therapeutic areas and geographies.
  • Deviations and variability introduced by remote data sources, including device inconsistencies and patient behaviour.
  • Site‐centric approaches to digital workflow integration that reduce burden and improve operational clarity.
  • Strategies to ensure patient safety and data integrity in remote and hybrid trial environments.

Moderator:


Panellists:

  • How AI can optimise protocol feasibility, reduce patient burden and improve operational predictability.
  • Emerging digital biomarkers and remote assessment technologies that expand the scope of measurable endpoints.
  • Predictive recruitment and retention models that support more accurate planning and resource allocation.
  • Regulatory considerations for AI‐supported decision‐making and the validation of algorithmic outputs.
  • How decentralisation enables faster early‐phase studies and more agile operational models for small teams.
  • Digital recruitment strategies tailored to niche, rare and geographically dispersed patient populations.
  • Cost‐efficiency gains achieved through remote procedures, simplified workflows and reduced site dependency.
  • Partnership models that allow biotech organisations to leverage CRO and technology expertise effectively.
  • Demonstrating real‐time dashboards that enhance operational oversight and support rapid decision‐making.
  • Presenting strategies for harmonising data from remote and site‐based sources into a single, coherent ecosystem.
  • Showcasing automated quality checks and deviation alerts that strengthen compliance and reduce manual review.
  • Highlighting how integrated datasets support regulatory submissions and improve evidence completeness.
  • Validated devices capable of producing clinical‐grade data suitable for regulatory acceptance.
  • Patient adherence challenges and presenting usability strategies that improve long‐term engagement.
  • How continuous monitoring can be integrated into trial workflows without overwhelming sites or patients?
  • Evidence showing how remote monitoring enhances safety oversight and patient experience.
  • Operational models that support multi‐country decentralised studies with consistent quality and oversight.
  • Regulatory variability across regions and strategies for harmonising digital processes internationally.
  • Technology harmonisation approaches that reduce fragmentation and improve operational efficiency.
  • Lessons learned from large‐scale deployments across diverse therapeutic areas.
  • Enterprise‐level strategies that embed digital trial capabilities into long‐term R&D planning.
  • Frameworks for integrating decentralisation into clinical operations without disrupting existing workflows.
  • Capability‐building initiatives that strengthen digital literacy and operational confidence across teams.
  • Metrics used to measure digital transformation impact across portfolios.
  • Approaches to ensure validity and reliability of digital endpoints collected through remote devices.
  • Statistical methods for managing device variability and patient‐generated data inconsistencies.
  • Hybrid methodologies that balance remote flexibility with scientific rigour.
  • Recommendations for future standards that strengthen methodological consistency.
  • Communication strategies that clearly explain digital trial expectations and reduce uncertainty.
  • Support models that help patients navigate remote participation challenges with confidence.
  • How co‐creation strengthens trust and improves the relevance of digital trial tools.
  • Approaches to ensure equitable access to digital platforms across diverse populations.
  • AI‐driven automation tools that reduce manual burden and streamline operational processes.
  • Intelligent scheduling and remote visit optimisation features that improve trial efficiency.
  • How workflow intelligence enhances predictability and reduces operational risk.
  • Collaboration models that align technology innovation with sponsor and CRO needs.
  • Combining insights from AI‐driven design, digital biomarkers and remote monitoring to shape next‐generation methodologies.
  • Aligning biotech agility, CRO global scaling and pharma transformation to build unified operational models.
  • Strengthening patient trust through transparent communication and inclusive digital engagement practices.
  • Translating unified data platforms, automation and national policy into sustainable digital ecosystems.

Moderator:


Panelists:

3rd DCT, Hybrid & Centralised Clinical Trials World Congress 2027 Europe

Co-located with the 8th Patient Centricity & Collaboration World Congress 2027 Europe 

Joint EXHIBIT & NETWORKING Area

2026 - Sponsors & Exhibitors

Newsletter Sign Up

No Spam - You will only receive relevant information on DECENTRALIZED CLINICAL TRIALS, and event updates

Delegate Tickets

Group Discounts Are Also Available

Non Profit / Academic

Verification Required
£499
  • Full Access - 2 Day Conference
  • All Day Refreshments & Lunches
  • Conference Documentations
  • Networking Drinks Reception

Standard Vendor Registration Rate

Vendors / Service / Solution Providers / Consultants / CRO's
£1999
  • Full Access - 2 Day Conference
  • All Day Refreshments & Lunches
  • Conference Documentations
  • Networking Drinks Reception

Standard Registration Rate

Pharma / Biotech
£1299
  • Full Access - 2 Day Conference
  • All Day Refreshments & Lunches
  • Conference Documentations
  • Networking Drinks Reception

Testimonials

what people say

Thank you for a good experience with the PARADIGM Global Events… very high level, very good Organization, we overpassed our expectatives, we will be pending for another congress related to pharmaceutical and biotech… we learned a lot, and i think that the content of agenda was state of the art, thank you again.
Salvador Berrios
ERP/ CRM / Product Configurator Manager
The consistently high quality of international faculty was most impressive. It was also obvious that they were carefully chosen not only for their particular expertise but also for their ability to communicate the subject matter to clinical and non-clinical participants alike. As market access consultant for pharma clients of various sizes, I now feel much better prepared to explain the nuances & dynamics involved in bringing their products to market. In addition, I am in a much better position to intelligently advice my clients & help them set realistic expectations
Thomas Martin
Associate Vice President, VCGA - Quintiles
I was impressed with the organization of this event. I attend many conferences per year and find the organizers on site to be detached and not focus on good service to the delegates. This team was even providing weather forecast warning to ensure everyone was aware and made appropriate plans. Well Done.
Adriana E. Manzi
PhD, Managing Director, Atheln, Inc

Previous events

Book Your Place Now! 

Register To Attend Now!

Take Advantage of the Super Early Bird Discount. Group Discounts Also Available. 

Location

Scroll to Top